Analyst Ratings For Smith & Nephew plc (LON:SN)
Today, Deutsche Bank reiterated its Sell rating on Smith & Nephew plc (LON:SN).
There are 5 Hold Ratings, 4 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Smith & Nephew plc (LON:SN) is Hold with a consensus target price of GBX 1,402.23 per share, a potential .
Some recent analyst ratings include
- 7/30/2018-Deutsche Bank Reiterated Rating of Sell.
- 5/14/2018-Berenberg Bank Reiterated Rating of Hold.
- 5/3/2018-Jefferies Financial Group Reiterated Rating of Buy.
- 4/25/2018-JPMorgan Chase & Co. Reiterated Rating of Overweight.
- 4/24/2018-Credit Suisse Group Reiterated Rating of Neutral.
About Smith & Nephew plc (LON:SN)
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Recent Trading Activity for Smith & Nephew plc (LON:SN)
Shares of Smith & Nephew plc closed the previous trading session at 1,364.00 −12.50 0.91% with 4.54 shares trading hands.